Miyajima Eriko, Imaizumi Hiroshi, Oshida Sayuri, Igarashi Keiko, Yoshida Muneki, Yanase Nobuo
Department of Health Care Center, Sagamino Hospital, Japan Community Health Care Organization Sagamino Hospital.
Sangyo Eiseigaku Zasshi. 2023 Jan 25;65(1):18-27. doi: 10.1539/sangyoeisei.2021-039-B. Epub 2022 Mar 19.
We investigated the antibody titer of spike-specific immunoglobulin G (IgG) antibodies after receiving coronavirus repair uridine ribonucleic acid (RNA) vaccine (BNT162b2, Pfizer) in health care workers.
At one hospital, health care workers received the vaccination between February and May 2021. A survey using questionnaires and spike-specific IgG antibody tests (Abbott) was conducted in 293 participants who had been vaccinated at least once and consented to this study at the time of medical checkups between April and May 2021. We calculated the antibody titer in each age group and days post-vaccination. We examined whether antibody titers of 4,000 AU/mL or higher (probability of high titer: approximately 95%, Abbott) were associated with adverse reactions after vaccination. In addition (1), the antibody titers at approximately 100 days after the second vaccination in 11 participants were remeasured. Furthermore (2), the antibody titers at approximately 260 days after the second vaccination in 13 participants were remeasured and compared with the initial measurements.
Of the participants, 276 were post-2 doses (A), 14 were post-1 dose (B), and 3 discontinued the second vaccination (C) at the time of health checkup. The median antibody titer was 11,045.8 AU/mL (50.7-40,000) in group A, 122.7 AU/mL (2.6-1,127.0) in group B, 27,099.3 AU/mL in one of group C who had recovered from coronavirus disease 2019 (COVID-19), and 574.2 AU/mL (283.3 and 865.1) in the other two of group C. The median antibody titer was the highest in those in their 20s, and there was a significant difference between those under and above 40 years of age. The median titer was the highest in 2 weeks to 1 month after the second vaccination. After the second dose, fatigue (≥ moderate) was associated with antibody titers of 4,000 AU/mL or higher. The antibody titers of 11 and 13 participants at approximately 100 and 260 days after the second vaccination were significantly lower than those at the first measurement, with median values of 2,838.0 AU/mL (832.9-5,698.6) and 512.0 AU/mL (154.0-1,220.0), respectively.
Antibody titers were higher in participants under 40 years of age than those 40 years or older. In addition, the percentage of high antibody titer (≧ 4,000 AU/mL) was higher in those who had severe fatigue after the second vaccination. The peak of antibody titer after the second dose was approximately 1 month, and the titer may decline gradually.
我们调查了医护人员接种新冠病毒修复尿苷核糖核酸（RNA）疫苗（BNT162b2，辉瑞公司）后刺突特异性免疫球蛋白G（IgG）抗体的滴度。
在一家医院，医护人员于2021年2月至5月期间接种了疫苗。在2021年4月至5月的体检时，对293名至少接种过一次疫苗并同意参与本研究的参与者进行了问卷调查和刺突特异性IgG抗体检测（雅培公司）。我们计算了每个年龄组和接种疫苗后的天数的抗体滴度。我们研究了4000 AU/mL或更高的抗体滴度（高滴度概率：约95%，雅培公司）是否与接种疫苗后的不良反应相关。此外，（1）对11名参与者在第二次接种后约100天的抗体滴度进行了重新检测。此外，（2）对13名参与者在第二次接种后约260天的抗体滴度进行了重新检测，并与初始检测结果进行了比较。
在健康检查时，参与者中276人接种了2剂（A组），14人接种了1剂（B组），3人在第二次接种时中断（C组）。A组的抗体滴度中位数为11,045.8 AU/mL（50.7 - 40,000），B组为122.7 AU/mL（2.6 - 1,127.0），C组中一名从2019冠状病毒病（COVID - 19）康复的参与者为27,099.3 AU/mL，C组另外两名参与者为574.2 AU/mL（283.3和865.1）。抗体滴度中位数在20多岁的人群中最高，40岁及以上和40岁以下人群之间存在显著差异。第二次接种后2周至1个月时滴度中位数最高。第二次接种后，疲劳（≥中度）与4000 AU/mL或更高的抗体滴度相关。11名和13名参与者在第二次接种后约100天和260天的抗体滴度显著低于首次检测结果，中位数分别为2,838.0 AU/mL（832.9 - 5,698.6）和512.0 AU/mL（154.0 - 1,220.0）。
40岁以下参与者的抗体滴度高于40岁及以上者。此外，第二次接种后出现严重疲劳的人群中高抗体滴度（≧4000 AU/mL）的比例更高。第二次接种后抗体滴度峰值约为1个月，且滴度可能会逐渐下降。
